Germline Genetic Testing After Cancer Diagnosis

Allison W Kurian, Paul Abrahamse, Allison Furgal, et al. JAMA. 2023 Jul 3;330(1):43-51

Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. A... Read More

Mar 24, 2026

Increased healthcare costs by later stage cancer diagnosis

November McGarvey, Matthew Gitlin, Ela Fadli,and Karen C. Chung. BMC Health Services Research (2022) 22:1155

Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand potential impac... Read More

Mar 24, 2026

Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer

Silvia Mignozzi, Claudia Santucci, Fabio Levi, et al. Eur J Cancer Prev. 2026 Mar 1;35(2):97-107.

We provided cancer mortality rate estimates for the year 2025 in six Latin American countries (Argentina, Brazil, Chile, Colombia, Cuba, and Mexico), focusing on prostate cancer. We extracted mortality data for all cancers combine... Read More

Mar 24, 2026

Cancer Incidence and Mortality Across 43 Cancer Registries in India

National Cancer Registry Programme Investigator Group; Prashant Mathur, Krishnan Sathishkumar, Priyanka Das,et al. JAMA Netw Open 2025 Aug 1;8(8):e2527805

Cancer is a significant global health concern, with India ranking second in Asia and third in the world in terms of cancer incidence. Regular monitoring and updates on cancer statistics are vital for assessing the impact and burde... Read More

Mar 23, 2026

Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021

Wenhui Ren 1, Xiangyu Guo 2, Zheng Liu, et al. Cancer 2025 Jan 15;131(2):e35712

Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. In 2021, China reported 385.84 thousand incident cases of female breast cancer, followed by cervical cancer, uterine cancer,... Read More

Mar 23, 2026

Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050

Yingying Li, Wenfu Song, Ping Gao, et al. BMC Cancer (2025) 25:330

Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Data from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021 provide criti... Read More

Mar 23, 2026